First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

作者：Alessandro Di Federico, Kaiwen Wang, Monica F. Chen, Adam A. Barsouk, Arianna Pagliaro, Lanyi N Chen, Francesca Rita Ogliari, Paul Stockhammer, Rajat Thawani, Shahm Raslan, Eleonora Gariazzo, Francesca Fusco, Grace Hambelton, Fabrizio Citarella, David J. Meyer, Mihaela D. Aldea, Andrea De Giglio, Joao V. Alessi, Federica Pecci, Francesco Gelsomino, Marcelo Petrocchi Corassa, Natalie I. Vokes, Xinan Wang, Dario de Biase, Fawzi Abu Rous, Phurin Areesawangkit, Omar Elghawy, Alessio Cortellini, Giulio Metro, Roberto Ferrara, Mark Magdi Awad, Aliyah Pabani, Joseph Christopher Murray, Federico Cappuzzo, Marina Chiara Garassino, Ibiayi Dagogo‐Jack, Gregory J. Riely, Michael J. Grant, Benjamin O. Herzberg, Andrea Ardizzoni, David Planchard, Bruce Evan Johnson, Corey Jay Langer, Michael David Offin, Marcelo Vailati Negrao, Biagio Ricciuti · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00409-7 · 被引用次数：16 · 研究领域：Lung Cancer Treatments and Mutations、Melanoma and MAPK Pathways、Cancer Immunotherapy and Biomarkers